Supplement Oversight
Supplement Oversight
Dietary supplements exist under separate regulatory assessment measures compared to prescription medicines’ requirements. The Federal Drug Administration does not need to examine supplement formulas before manufacturers market their products. FDA regulations mainly rely on Current Good Manufacturing Practices (CGMPs) and post-market surveillance to enforce safety standards within the dietary supplement industry (CBS Mornings, 2019). The regulatory system has triggered public discussions about safety monitoring and protection standards.
The FDA’s guidelines establish CGMP as an integrity standard that regulates manufacturing safety while emphasizing facility sanitation and risk identification in the production process for product safety assurance (FDA, 2020). FDA regulations allow supplements to enter the market without requiring testing that verifies product effectiveness or claimed benefits. This presents dangers to consumer safety. Unlike prescription drugs, supplements enter the market by avoiding the need for clinical evidence to support their health claims. Consequently, false advertising and unverified claims are prevalent, as noted in FDA alerts about potentially harmful supplements marketed with promises of treating dementia or cancer.
Brown (2017) notes that serious concerns emerge from functional ingredient contamination alongside product adulteration and new dietary ingredient (NDI) implementation despite most dietary supplement adverse events being minor in nature. Categories like sexual enhancement, weight loss, and bodybuilding supplements are particularly prone to these problems. The FDA possesses the power to stop harmful products, but such actions usually start after marketing, thus potentially risking public health.
Supplements need better regulatory oversight moving into the future. This oversight needs more powerful pre-market assessments combined with aggressive enforcement of advertising rules. According to Brown (2017), faster response systems during post-marketing surveillance will help protect consumers from risks. In addition, urgent action must focus on educating the public about medication interactions and false claims concerning dietary supplements.
Future supervision of supplements will require federal agencies to work together, including the FDA and Federal Trade Commission, to monitor false advertising. The rapid growth of the supplement industry highlights the urgency of a strong regulatory system to protect consumer health and maintain product purity.
References
Brown, A. C. (2017). An overview of herb and dietary supplement efficacy, safety, and government regulations in the United States with suggested improvements. Part 1 of 5 series. Food and Chemical Toxicology, 107, 449-471.
CBS Mornings. (2019, February 22). FDA raises concerns about potentially harmful dietary supplements [Video]. YouTube. https://www.youtube.com/watch?v=1BwDuMlBCQs
CGMPs for food and dietary supplements. (2020, January 31). U.S. Food and Drug Administration. https://www.fda.gov/food/guidance-regulation-food-and-dietary-supplements/current-good-manufacturing-practices-cgmps-food-and-dietary-supplements
CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER
Supplement Oversight
